Synairgen plc in Drug Partnership Talks After Study Results

Synairgen Plc (SNG) is in talks with potential partners following the results of a study of an experimental medicine targeting infections that trigger asthma attacks, Chief Executive Officer Richard Marsden said. Synairgen is speaking with larger drugmakers that will help the company with regulatory filings and marketing the product, SNG001, Marsden said in an interview at the European Respiratory Society’s annual meeting in Vienna yesterday. In a mid-stage study of 134 adults who caught a cold, SNG001 was effective in the most difficult-to-treat patients, preventing asthma symptoms from getting worse during the first week of infection and treatment. There was also a 65 percent reduction in the number of patients who experienced asthma attacks during the treatment period compared with a group on placebo, the company said.

Back to news